Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: This systematic review and network meta-analysis aimed to provide a complete hepatotoxicity profile, hepatotoxicity spectrum, and safety ranking of immune checkpoint inhibitor drugs for cancer treatment. Methods: PubMed, Embase, Scopus, CINAHL, Web of Science, psycINFO, Cochrane Library, and ClinicalTrials.gov. websites were searched, and a manual search of relevant reviews and trials up to January 1, 2022, was undertaken. Head-to-head III randomized controlled trials comparing any 2 or 3 of the following treatments or different doses of the same immune checkpoint inhibitor drug were included: programmed death 1 (PD-1), programmed death ligand 1, and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) inhibitors and conventional therapy. We included 106 randomized trials (n=164,782) containing 17 treatment arms. Results: The overall incidence of hepatotoxicity was 4.06%. The rate of fatal liver adverse events was 0.07%. The programmed death ligand 1 inhibitor+targeted therapy drug+chemotherapy group had the highest risk of treatment-related increases in all-grade alanine aminotransferase and aspartate aminotransferase levels, and the differences were significant. For immune-related hepatotoxicity, no significant difference was found between PD-1 and CTLA-4 inhibitors for all-grade hepatotoxicity; however, CTLA-4 inhibitors were associated with a higher risk of grade 3–5 hepatotoxicity than PD-1 inhibitors. Conclusions: The highest incidence of hepatotoxicity and fatality was observed with triple therapy. The overall incidence of hepatotoxicity was similar between different dual regimens. For immune checkpoint inhibitor monotherapy, the overall risk of immune-mediated hepatotoxicity related to CTLA-4 inhibitors did not differ significantly from that of PD-1 inhibitors. There was no direct relationship between the risk of liver injury and drug dose, whether monotherapy or combination therapy was used.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients who receive anti-CTLA-4 monoclonal antibody infusions, dual immune checkpoint inhibitor (ICI) therapy, or a combination of ICI with cytotoxic chemotherapy or targeted therapies are at increased risk of ILICI in comparison to monotherapy PD-1/PD-L1 inhibitors. 44”
From The contemporary epidemiology, causes, and management of drug-induced liver injury (2026) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
General methods for monitoring convergence of iterative simulations
Brooks, S. P., & Gelman, A. (1998) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.1998.10474787 · Cited by 6,045
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Salanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642 · cited 3×
“This may confuse clinicians between TRAEs and ILICI.”
ResultThompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0013 · Cited by 570
Research works printed but not linked: 39
- Leach, 1996, Enhancement of antitumor immunity by CTLA-4 blockade, Science, 271, 1734, 10.1126/science.271.5256.1734 · DOI · Paper page
- Sharma, 2011, Novel cancer immunotherapy agents with survival benefit: recent successes and next steps, Nat Rev Cancer, 11, 805, 10.1038/nrc3153 · DOI · Paper page
- Long, 2016, Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study, Ann Oncol, 27, 1940, 10.1093/annonc/mdw265 · DOI
- Reck, 2018, Impact of Nivolumab versus Docetaxel on health-related quality of life and symptoms in patients with advanced squamous non-small cell lung cancer: results from the CheckMate 017 study, J Thorac Oncol, 13, 194, 10.1016/j.jtho.2017.10.029 · DOI
- Callahan, 2011, Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis, J Clin Oncol, 29, 2505, 10.1200/jco.2011.29.15_suppl.2505 · DOI · Paper page
- Alsaab, 2017, PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome, Front Pharmacol, 8, 561, 10.3389/fphar.2017.00561 · DOI · Paper page
- Jim, 2021, Immune checkpoint inhibitor therapy toxicities, JAMA, 326, 87, 10.1001/jama.2021.6030 · doi:10.1001/jama.2021.6030
- Losser, 1996, Mechanisms of liver damage, Semin Liver Dis, 16, 357, 10.1055/s-2007-1007249 · DOI
- Naing, 2020, Being realistic and optimistic in curing cancer, J Immunother Precis Oncol, 1, 53, 10.4103/JIPO.JIPO_20_18 · DOI
- Paracha, 2017, PCN194—Rate of hospitalization due to adverse event and length of stay for Atezolizumab in second and third line metastatic non-small lung cancer (NSCLC) using phase 3 Oak study, Value Health, 20, A447, 10.1016/j.jval.2017.08.3022 · doi:10.1016/j.jval.2017.08.3022
- Wang, 2019, Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis, JAMA Oncol, 5, 1008, 10.1001/jamaoncol.2019.0393 · DOI · Paper page
- Gelman, 1996, Markov chain Monte Carlo methods in biostatistics, Stat Methods Med Res, 5, 339, 10.1177/096228029600500402 · DOI · Paper page
- Hong, 2021, Meta-analysis of rare adverse events in randomized clinical trials: Bayesian and frequentist methods, Clin Trials, 18, 3, 10.1177/1740774520969136 · DOI
- Gandhi, 2018, Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer, N Engl J Med, 378, 2078, 10.1056/NEJMoa1801005 · DOI · Paper page
- Yang, 2020, Risk of gastrointestinal adverse events in cancer patients treated with immune checkpoint inhibitor plus chemotherapy: a systematic review and meta-analysis, Front Oncol, 10, 197, 10.3389/fonc.2020.00197 · DOI
- Parlati, 2018, Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: a retrospective study, J Hepatol, 69, 1396, 10.1016/j.jhep.2018.08.014 · DOI
- Fu, 2021, Immune checkpoint inhibitor associated hepatotoxicity in primary liver cancer versus other cancers: a systematic review and meta-analysis, Front Oncol, 11, 650292, 10.3389/fonc.2021.650292 · DOI · Paper page
- Lin, 2020, A systematic review and meta-analysis of immune-mediated liver dysfunction in non-small cell lung cancer, Int Immunopharmacol, 83, 106537, 10.1016/j.intimp.2020.106537 · DOI
- Deng, 2019, The relative risk of immune-related liver dysfunction of PD-1/PD-L1 inhibitors versus chemotherapy in solid tumors: a meta-analysis of randomized controlled trials, Front Pharmacol, 10, 1063, 10.3389/fphar.2019.01063 · doi:10.3389/fphar.2019.01063
- Balibegloo, 2021, Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: a systematic review and meta-analysis, Int Immunopharmacol, 96, 107796, 10.1016/j.intimp.2021.107796 · DOI
- O’Kane, 2017, Monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer, Oncologist, 22, 70, 10.1634/theoncologist.2016-0164 · DOI · Paper page
- Ma, 2018, The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis, Front Pharmacol, 9, 1430, 10.3389/fphar.2018.01430 · DOI
- Su, 2018, Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment, J Cancer, 9, 1614, 10.7150/jca.24200 · DOI
- Wang, 2017, Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data, Int J Cancer, 141, 1018, 10.1002/ijc.30678 · DOI · Paper page
- Rosner, 2017, Acute kidney injury in patients with cancer, N Engl J Med, 376, 1770, 10.1056/NEJMra1613984 · DOI · Paper page
- Peng, 2015, Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-κB to foster an immunosuppressive tumor microenvironment in ovarian cancer, Cancer Res, 75, 5034, 10.1158/0008-5472.CAN-14-3098 · DOI · Paper page
- Petrelli, 2020, Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis, J Immunother, 43, 1, 10.1097/CJI.0000000000000300 · DOI
- Su, 2019, Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis, Front Immunol, 10, 108, 10.3389/fimmu.2019.00108 · DOI · Paper page
- Chang, 2020, Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: a systematic review and network meta-analysis, JAMA Netw Open, 3, e201611, 10.1001/jamanetworkopen.2020.1611 · DOI
- Facchinetti, 2020, Adding PD-1/PD-L1 inhibitors to chemotherapy for the first-line treatment of extensive stage small cell lung cancer (SCLC): a meta-analysis of randomized trials, Cancers (Basel), 12, 2645, 10.3390/cancers12092645 · DOI
- Wolchok, 2017, Overall survival with combined nivolumab and ipilimumab in advanced melanoma, N Engl J Med, 377, 1345, 10.1056/NEJMoa1709684 · DOI · Paper page
- Shoushtari, 2018, Measuring toxic effects and time to treatment failure for Nivolumab plus Ipilimumab in melanoma, JAMA Oncol, 4, 98, 10.1001/jamaoncol.2017.2391 · DOI · Paper page
- Fife, 2008, Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways, Immunol Rev, 224, 166, 10.1111/j.1600-065X.2008.00662.x · DOI · Paper page
- Jiang, 2019, Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis, Ther Clin Risk Manag, 15, 293, 10.2147/TCRM.S191022 · DOI
- Wang, 2017, Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis, Front Pharmacol, 8, 730, 10.3389/fphar.2017.00730 · DOI · Paper page
- Kleffel, 2015, Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth, Cell, 162, 1242, 10.1016/j.cell.2015.08.052 · DOI · Paper page
- Rizvi, 2015, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348 · DOI · Paper page
- Peeraphatdit, 2020, Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation, Hepatology, 72, 315, 10.1002/hep.31227 · DOI · Paper page
- Zhao, 2017, Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors, Ann Oncol, 28, 2002, 10.1093/annonc/mdx235 · DOI · Paper page
Cited by
The contemporary epidemiology, causes, and management of drug-induced liver injury
Swanson, L., & Fontana, R. J. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000001011
Metadata
- Authors
- Zheng, C., Huang, S., Lin, M., Hong, B., Ni, R., Dai, H., Lin, X., & Yang, J.
- Affiliations
- Fuqing City Hospital Affiliated to Fujian Medical University, Fuzhou, China
- College of Pharmacy, Fujian Medical University, Fuzhou, China
- Affiliated Fuzhou First Hospital of Fujian Medical University, Fuzhou, China
- Venue
- Hepatology Communications
- Published
- 2023-02-20
- Volume
- 7
- Issue
- 3
- Pages
- e0063-e0063
- ISSN
- 2471-254X
- Cited by
- 49
- References
- 5
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known. https://app.cochat.ai/papers/10.1097/hc9.0000000000000063
- The paper
- Zheng, C., Huang, S., Lin, M., Hong, B., Ni, R., Dai, H., Lin, X., & Yang, J. (2023). Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known. Hepatology Communications. https://doi.org/10.1097/hc9.0000000000000063
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.